Head-to-head · Cost-Efficiency Index
Invigor Medical vs Piper
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalPiper
Nationwide shoppers who want both molecules disclosed at fair prices and will do their own diligence on the pharmacy.
Visit PiperThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 82. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. Piper still earns a B− — Nationwide shoppers who want both molecules disclosed at fair prices and will do their own diligence on the pharmacy.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | Piper |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 82/100 |
| Semaglutide / mo | $199/mo | $135/mo |
| Tirzepatide / mo | $339/mo | $199/mo |
| Semaglutide / yr (modeled) | $2,388 | $1,620 |
| Tirzepatide / yr (modeled) | $4,068 | $2,388 |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #4 | #22 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
Piper
82/100Where the value is
- Both molecules disclosed — $135 semaglutide / $199 tirzepatide — for clean cost modeling
- Nationwide all-50 access with predictable flat pricing
- Straightforward to model for a full year
The tradeoffs
- Not LegitScript-certified, so pharmacy oversight is harder to verify
- Compounded only — no brand-name or oral route
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.